Fingolimod Hydrochloride

• 

  Subject Areas on Research

  • Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. 
  • Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. 
  • FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. 
  • Modulation of adaptive immune responses by sphingosine-1-phosphate. 
  • Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease. 
  • S1P-Dependent trafficking of intracellular yersinia pestis through lymph nodes establishes Buboes and systemic infection. 
  • Should we B-leavin' now? 
  • Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma. 
  • Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. 
  • The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. 
  • The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. 
  • The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.